Address: 3791 Jalan Bukit Merah, #07-21 E-Centre, Redhill, Singapore 159471 ,Singapore
Tel: (+65) 6285 3683
Web: http://www.leo-pharma.com/
LEO Pharma is an independent, research-based pharmaceutical company. The company develops, manufactures and markets pharmaceutical drugs to dermatologic and thrombotic patients in more than 100 countries globally. To realise their vision of becoming the preferred dermatology care partner improving people’s lives around the world, they are expanding into new regions and markets, reaching more patients and societies with drugs and therapies that address unmet medical needs. LEO Pharma has its own sales forces in 61 countries and employs around 5,000 employees worldwide. The company is headquartered in Denmark and is wholly owned by the LEO Foundation.
Dermatological products
In recent times, French pharma industry associations have been arguing vociferously about the need to proactively ‘re-industrialise’ French pharma to counter the distortionary impact of protectionist policies and massive state…
France and Denmark have a rich history of healthcare collaboration, from basic research to clinical trials, as well as major manufacturing investments. What links these two nations, and what are…
Valued fifth globally in terms of overall revenues and enjoying year-on-year growth rates exceeding five percent, the French pharma market is undeniably one of the great global life science powerhouses,…
From the perspective of international pharmaceuticals developers, Latin America can be considered a region of exceptional potential owing to solid market fundamentals and significant untapped opportunities. “I am convinced that…
Latin America’s largest and most dynamic pharma market is booming. Despite sluggish macroeconomic growth, agile local firms are consolidating their positions to serve Brazilian patients, while a spate of technology…
Haig Yeghiaian, General Manager at LEO Pharma Brazil, brings extensive therapeutic area expertise spanning HIV, nephrology, and dermatology to his leadership of the company’s multifaceted Brazilian operations. Under his stewardship,…
France’s minority government has forced through a Social Security & Healthcare Bill for 2026 containing EUR five billion in healthcare cuts. For the country’s beleaguered innovative pharma industry, this Bill…
LEO Pharma – a global heavyweight in the dermatology field – is undergoing a period of renewal, combining a stronger focus on innovation with a cultural transformation aimed at greater…
While Big Pharma giants chase blockbuster drugs across multiple therapeutic areas, three Danish mid-cap companies are pursuing a different path to survival. Facing mounting pressures and global competition, ALK, LEO…
Once a quiet legacy player in dermatology, LEO Pharma is re-emerging with renewed focus and ambition under CEO Christophe Bourdon. With global leadership experience at Amgen and Alexion, Bourdon is…
LEO Pharma has been in the midst of a shakeup since the beginning of 2022. After naming a new CEO and announcing a major restructuring, the Danish dermatology pharma has…
After 15 years of economic struggles coupled with political swings to the left and right, Greece seems to be on its surest footing in decades. Indeed, the Economist observed that…
See our Cookie Privacy Policy Here
